GLP-1 vs Amylin Agonists

TL;DR

• GLP-1 agonists (semaglutide, tirzepatide, retatrutide) work through the incretin system. Slow gastric emptying, suppress appetite, improve insulin response.
• Amylin agonists (cagrilintide, pramlintide) work through the amylin receptor. Also slow gastric emptying and suppress appetite, but through a separate hormone pathway.
• The shorthand: these are two different hormone systems that do similar jobs. Combining them is additive, which is why CagriSema is generating so much interest.

If you only remember one thing: amylin isn't a weaker cousin of GLP-1. It's a different system that hits the same outcomes through a different door. Stacking them adds up.

The headline difference, in one sentence

GLP-1 and amylin are different hormones from different tissues with different receptors — but both end up telling the brain "you're full" and the stomach "slow down."

What each class actually is

What amylin is, briefly

Amylin (also called IAPP — islet amyloid polypeptide) is a hormone released by the pancreas alongside insulin every time you eat. Its job is to slow gastric emptying (reducing post-meal glucose spikes), suppress glucagon secretion after meals (so the liver doesn't dump glucose when you just ate), and act on hindbrain appetite centers to increase satiety.

People with type 1 diabetes not only lack insulin but also lack amylin, which is why post-meal glucose control is hard with insulin alone. Pramlintide (synthetic amylin analog) was approved in 2005 as a co-treatment for insulin-dependent diabetes.

Cagrilintide is a newer, long-acting amylin analog designed for weekly dosing, currently in trials both as a solo weight-loss therapy and combined with semaglutide.

What CagriSema is, briefly

CagriSema = cagrilintide (amylin agonist) + semaglutide (GLP-1 agonist), in a single weekly injection. Novo Nordisk's combination product, currently in Phase 3 trials.

The rationale: GLP-1 agonism and amylin agonism are additive — two different hormone systems both telling the body "stop eating, slow down digestion, reduce food intake." Preliminary trial data suggests CagriSema weight-loss numbers compete with tirzepatide and potentially retatrutide, using a completely different mechanism stack.

Pick a GLP-1 agonist if...

• You want a proven, approved option with extensive trial data.
• The research target is weight loss OR diabetes glycemic control (GLP-1 agonists are approved for both).
• You're starting fresh and want the most-studied class in this metabolic category.
• You're interested in the GLP-1 cardiovascular outcomes data that doesn't yet exist for amylin agonists.
• You want pharmacy availability and insurance coverage.

Pick an amylin agonist if...

• You're researching amylin biology specifically — its role in post-meal glucose regulation and satiety.
• You want to study the insulin + amylin system together — pramlintide is approved specifically as an insulin co-therapy.
• You're tracking cagrilintide's development as a potential next-generation weight-loss therapy.
• You're interested in CagriSema as an alternative to tirzepatide-class dual mechanisms.
• You want to see what non-incretin-based appetite suppression looks like.

Pick the combination (CagriSema) if...

• You're researching maximum additive effect from stacking hormone classes.
• You want to study whether amylin + GLP-1 matches or exceeds GIP-based dual agonism (tirzepatide).
• You're interested in the multi-hormone future of metabolic therapy.
• You accept the investigational status — CagriSema isn't FDA-approved as of 2026.

Honest tradeoffs

• Amylin data is thinner: GLP-1 agonists have massive RCT and real-world evidence bases. Amylin agonists (beyond pramlintide) are mostly in active trials. Cagrilintide's long-tail safety data isn't mature.
• Cagrilintide is not available at pharmacy (as of 2026) — it's trial-only and research-supply. GLP-1 agonists are everywhere by comparison.
• CagriSema is a combination: one weekly injection contains both. It's not possible (or advisable) to mimic by mixing two separately-sourced compounds in research settings.
• Side effects partially overlap: both classes produce GI side effects (nausea, early satiety). Stacking amylin and GLP-1 can stack GI symptoms during titration, though trial data suggests this is manageable.
• Weight loss numbers: GLP-1 mono-agonism (semaglutide) ~15%. Dual agonism (tirzepatide) ~21%. CagriSema preliminary data ~22-25% in Phase 2. Real comparison numbers are still emerging.
• Mechanism diversity matters: if you're only hitting GLP-1 harder, you're stacking effects on the same hormone system (see tirzepatide vs retatrutide). Amylin stacking hits a different system — potentially more durable, potentially with different side-effect math.

Quick decision shortcut

The bigger picture

Metabolic peptide therapy in 2026 is moving through a generational shift. The first wave (GLP-1 mono-agonists) worked. The second wave (dual and triple agonists) works more. The third wave — currently playing out — is about combining different hormone classes rather than adding more receptors to the same one.

Amylin agonism is one of those other classes. There will be others: glucagon-like analogs on their own, various gut-brain peptides, and combinations we haven't named yet. The interesting question isn't "which GLP-1 is best" — it's "which combination of hormone systems produces the best outcomes with the best tolerability."

Where to read more

• The full incretin-family breakdown: Semaglutide vs Tirzepatide vs Retatrutide.
• Head-to-head GLP-1 pairings: Semaglutide vs Tirzepatide, Tirzepatide vs Retatrutide.
• Individual compounds: Semaglutide, Tirzepatide, Retatrutide.

Important context

GLP-1 agonists are FDA-approved prescription medications with extensive human trial data. Amylin agonists: pramlintide is FDA-approved (2005); cagrilintide and CagriSema are investigational and not approved for any indication. Compounded versions of these compounds vary in regulatory status by jurisdiction. Nothing on this page is medical advice.